Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.